As a chemistry service focused company, Cheminpharma LLC applies a non-traditional business model of using revenues generated from their business to fund novel preclinical candidates. Cheminpharma designed and synthesized a novel macrocyclic inhibitor CIP-137401, which has the potential to be a lead candidate for the orphan disease LMNA mutated cardiomyopathy and a variety of cancers arising from mutations in the Ras pathway.
Allomek Therapeutics, a spin-off company from Cheminpharma was established to focus on developing CIP-137401. As a UCONN Technology Incubation Program (TIP) Incubator company, Allomek has received pre-seed funding from Connecticut Innovations and was also awarded phase-I STTR in collaboration with Columbia University. Both Cheminpharma and Allomek were nominated the “Most Promising Life Science Product” by CT Technology Council.
Uday Khire, Founder, CEO of Cheminparma LLC and Cofounder of Allomek Therapeutics, will share his experience managing two very different business operations, establishing funding for R&D, and his vision for the businesses.
Uday Khire, Ph.D. MBA, a synthetic chemist with over 17 years of experience in medicinal chemistry/drug discovery. He worked as a medicinal chemist on numerous preclinical drug discovery projects in the therapeutic areas of diabetes, obesity and oncology at Bayer Research Center (BRC) in West Haven. Uday is a co-inventor of a novel multi-kinase inhibitor, developed jointly by Bayer and Onyx and is approved as first line therapy for kidney and liver cancer in US and other major markets. He has authored numerous peer-reviewed international scientific publications and is inventor of many patents/patent applications.